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Abstract 
Background and Aims. To test prospective associations between cannabis disorder 
symptoms/frequency of cannabis use and health issues and to investigate stability vs transience 
in cannabis use trajectories. 
Design. Two waves of data collection from the longitudinal Cohort Study on Substance Use Risk 
Factors (C-SURF). 
Setting. A representative sample of young Swiss men in their early twenties from the general 
population. 
Participants. A total of 5,084 young men (mean age 19.98 ± 1.19 years at Time 1). 
Measurements. Cannabis use (lifetime use, frequency of use, cannabis disorder symptoms) and 
self-reported measures of health issues (depression, mental/physical health, health consequences) 
were assessed. Significant changes in cannabis use were tested using t-test/Wilcoxon rank test 
for paired data. Cross-lagged panel models provided evidence regarding longitudinal 
associations between cannabis use and health issues. 
Findings. Most of the participants (84.45%) remained in the same use category and cannabis use 
kept to similar levels at Times 1 and 2 (p=.114 and p=.755). Cross-lagged panel models showed 
that cannabis disorder symptoms predicted later health issues (e.g. depression, β=.087, p<.001; 
health consequences, β= .045, p<.05). The reverse paths from health issues to cannabis disorder 
symptoms and the cross-lagged panel model between frequency of cannabis use and health 
issues were non-significant. 
Conclusions. Patterns of cannabis use showed substantial continuity among young people in 
their early twenties. The clinically important measure of cannabis use was the number of 
symptoms of cannabis use disorder rather than the frequency of cannabis use. 
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Introduction 
Cannabis is the most widely used illicit drug worldwide, and young adulthood is a period of 
active cannabis use (1, 2). Numerous studies have underlined the detrimental effects of cannabis 
use on health, including neuropsychological and cognitive impairment (3-6), and mental health 
problems (7-11). However, although neuropsychological impairment has been studied through 
causal pathways (3, 12), debate continues about the causal association of cannabis use and 
mental health problems, and the incidence of psychiatric disorders and schizophrenia that result 
from repeated cannabis use in teenage years and young adulthood (11, 13-18). 
Moreover, there is also a debate about which measure of cannabis use should be taken into 
account: does cannabis dependence alone lead to mental health problems, or are frequent 
cannabis users (i.e. not necessarily dependent cannabis users) also affected by an increase in 
detrimental health issues? Frequency of use refers to cannabis use, which may be used in a non-
problematic way, without any negative consequences. Cannabis dependence is a substance-use 
disorder, which implies frequent (daily) use and negative effects on users’ live. Some studies 
have reported that both frequency of cannabis use and cannabis dependence are linked to mental 
health problems (11, 18-21), but others have pointed out that frequent cannabis use is not 
associated with increased internalising disorders such as depression (19, 22, 23). This study 
aimed to fill in these gaps, by testing causal pathways from frequency of cannabis use and 
cannabis dependence to mental health issues (mental health problems, depression). Additional 
health issues were added to investigate the consequences of cannabis use in young adulthood 
more precisely (e.g. physical health problems and health consequences).  
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Investigating trajectories of cannabis use in early adulthood was an additional aim. Several 
studies have shown that cannabis use is stable during late adolescence and early adulthood (24-
28). About 80% of young adults remain in the same category of use (cannabis use/non-use). For 
example, Schulenberg et al (24), Arrial et al. (26) and Brook et al. (27) reported 80%, 87.2% and 
81.4% of continuity in cannabis use/non-use, respectively. However, the focus of these studies 
was rarely to investigate trajectories themselves because the initiation of cannabis use has often 
already occurred by the late teenage years or early twenties (29, 30). They focused rather on 
identifying protective factors or risk factors surrounding increased cannabis use and the 
detrimental consequences of that use. Indeed, this interesting result of cannabis use stability 
across late adolescence and early adulthood has not yet been highlighted. 
 
Thus, this study’s aims were twofold: 1) to investigate cannabis use trajectories and find out 
whether the patterns of cannabis use among young adults were stable or transient; 2) to test 
prospective pathways between symptoms of cannabis use disorder/frequency of cannabis use and 
health issues (mental health issues and more general health issues). 
 
Method 
Participants and procedures 
The data presented here were collected in the Cohort Study on Substance Use Risk Factors (C-
SURF), a longitudinal study designed to assess substance use patterns and their related 
consequences in young Swiss men. Participants were enrolled in three of Switzerland’s six army 
recruitment centres. These three centres cover 21 of the country’s 26 cantons (including all 
French-speaking ones) and are located in Lausanne (French-speaking), Windisch and Mels 
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(German-speaking). There is no pre-selection for this conscription, and all young men around 20 
years-old are evaluated to determine their eligibility for military, civil or no service because 
army recruitment is obligatory in Switzerland. Thus, all young Swiss men around 20 years-old 
were eligible for study inclusion. The recruitment centers were only used to enroll participants. 
Assessment of baseline and follow-up data was carried out outside the army environment and 
independently of eligibility for military service. Participants who gave a written consent to participate in 
recruitment centers were invited two weeks later by mail or email to fill in a paper and pen or an online 
questionnaire, according to the favorite way they indicated in the written consent. For follow-up, all the 
participants were similarly invited to fill in the questionnaire, by mail or email. 
Baseline data (Time 1) were collected between September 2010 and March 2012, and follow-up 
data (Time 2) were collected between January 2012 and April 2013, with an average of 15 ± 2.8 
months between the two assessments. A total of 5,990 participants filled in the baseline 
questionnaire, and 5,223 (87.2%) filled in the follow-up questionnaire. Missing values were 
listwise deleted, and the final sample consisted of 5,084 participants (95.6% of the follow-up 
sample). A previous study about sampling and non-response bias can be found in Studer et al. 
(31). As this study reported that non-response bias was small in the sample and because missing 
values were less than 5%, listwise deletion was preferred to multiple-imputation which can 
introduce bias in statistical inference. The study protocol (Protocol No. 15/07) was approved by 
Lausanne University Medical School’s Clinical Research Ethics Committee. 
 
Measures 
Prevalence of cannabis use. Participants were asked if they had used cannabis (hashish, 
marijuana or grass) during the past 12 months. This question allowed the identification of 
changes in cannabis use: non-users (participants who had not used cannabis in the 12 months 
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prior to Times 1 and 2), continuing users (participants who had used cannabis in the 12 months 
prior to both Times 1 and 2), late onset users (participants whose first cannabis use occurred in 
the 12 months prior to Time 2, and were non-users at Time 1), and matured out users 
(participants who used cannabis in the 12 months prior to Time 1, but not in the 12 months prior 
to Time 2). Age of first cannabis use was also assessed at Time 1. For late onset users, first use 
was settled to actual age at Time 2. Table 1 gave an overview of the subgroups of cannabis users. 
 
Insert Table 1 about here 
 
Frequency of cannabis use. Frequency of cannabis use was assessed at Times 1 and 2 by asking 
participants how many times they had used cannabis during the past 12 months. Answers were 
collected on a 5-point scale coded 1 for ‘monthly or less’, 2 for ‘2–4 times a month’, 3 for ‘2–3 
times a week’, 4 for ‘4–5 times a week’, and 5 for ‘every day or almost every day’. 
Cannabis disorder symptoms. At Times 1 and 2, participants were asked about symptoms of 
cannabis use disorder during the past 12 months using the Cannabis Use Disorder Identification 
Test, CUDIT (32). This is a ten-item assessment tool for evaluating cannabis misuse (abuse and 
dependence); it is scored 0 (no misuse) to 40 (misuse). A continuous score was used to better 
capture variability among cannabis users. 
Depression. The Major Depressive Inventory (ICD-10)–WHO-MDI was used at Times 1 and 2 
to assess levels of depression (33, 34). This is a ten-item questionnaire that screens answers on a 
six-point scale from 0 (never) to 5 (all the time). A continuous scale (ranging from 0 to 50) was 
used instead of a cut-off, to better capture variability across the range of symptoms for 
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depression and the severity of depression states. The total scale score of MDI has been 
previously described as a sufficient statistic (33). 
Mental and physical health. Physical and mental health were assessed at Times 1 and 2 using the 
Short Form Health Survey (SF-12) (35), with two subscales: the mental component summary 
(dealing with mental and social health), and physical component summary (dealing with physical 
health). These subscales were calculated according to their standard scoring, giving 2 composite 
scores ranging from 0 (health problem) to 100 (no health problem). The mental component 
summary primarily covered sadness, nervousness and depression. 
Health consequences. At Times 1 and 2, seven health consequences were selected from standard 
instruments (36-39). These were not explicitly substance related as the use of substance-
attributed consequences introduces bias (40). They included accident/injury, admittance to an 
emergency department, attempted suicide, need for medical treatment, overnight stay in hospital, 
outpatient surgery, and treatment of an accident/injury in an emergency department. Each 
consequence was coded 0 if it had not occurred in the past 12 months and 1 if it had occurred at 
least once during the past 12 months. A mean score was then calculated.  
 
Statistical analyses 
Two series of analyses investigated the two aims of the study: investigating cannabis use 
trajectories and testing the causal pathways between cannabis use and health issues. 
 
1) Cannabis use trajectories 
First, descriptive statistics for the whole sample (N=5,084) were calculated to investigate 
patterns of cannabis use at Times 1 and 2. Associations of cannabis use (cannabis disorder 
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symptoms, frequency of cannabis use) with health-related outcomes were tested with Spearman 
correlations. 
Then, significant changes in cannabis use across time were tested using the t-test for paired 
samples for number of cannabis disorder symptoms and the related-samples Wilcoxon signed 
rank test for frequency of cannabis use. These analyses involved cannabis users and not non-
cannabis users (N=1,939) including participants who used cannabis at Time 1 and/or Time 2, 
with measurements on cannabis use were settled at zero (cannabis disorder symptoms and 
frequency of cannabis use) for those who had not used cannabis in the 12 months prior to Times 
1 or 2.  
 
2) Longitudinal pathways between cannabis use and health issues 
To provide evidence regarding the direction of the relationship between cannabis use and health 
issues, cross-lagged panel models were used. These models indicate predominant causal 
influences and allow an examination of whether one variable predict subsequent changes in the 
other variable, and of the reserve lagged associations. The ‘causal winner’ (41) is the variable 
that predicts the other without being predicted itself in return.  
Two models were tested: one for the cannabis disorder symptoms, and the other for frequency of 
cannabis use. Models included a) autoregression (i.e. the regression between the same variable at 
Time 1 and Time 2), b) synchronous correlations (i.e. correlations between different variables at 
the same time point), c) causal paths with cross-lagged paths from cannabis use to health issues, 
and d) reverse-causal paths with cross-lagged paths from health issues to cannabis use. Figure 1 
presents the model for the cannabis disorder symptoms. The same model was tested for 
frequency of cannabis use, with the difference that frequency of cannabis use was an ordinal 
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variable, so 5 dichotomous variables were used for Time 1 (independent variable), with 
frequency of cannabis use equal zero as the reference group. Maximum likelihood estimation 
was used for the cannabis disorder symptoms model and robust weighted least squares estimator 
(WLSMV) for the frequency of cannabis use model. Linear regressions were computed for 
continuous outcomes and probit regressions with theta parameterization for ordinal outcomes. 
These two models were tested for all cannabis users, and then only for the subgroup of 
continuing cannabis users. As the results were very similar (the only difference was that the path 
coefficients were a little higher for continuing cannabis users), only the models including all 
cannabis users are presented. Cross-lagged panel models were tested controlling for age of first 
cannabis use and language (French- and German-speaking); the model for cannabis disorder 
symptoms was tested controlling for frequency of cannabis use. Cross-lagged panel models were 
carried out using Mplus 6 (42); other analyses used SPSS 21. 
 
Insert Figure 1 about here 
 
Results 
Cannabis use trajectories 
At Time 1, participants were 19.98 ± 1.19 years old. Descriptive statistics are shown in Table 2. 
Most of the participants (84.5%) remained in the same use category and only 15.5% changed 
their cannabis use between Times 1 and Time 2. 
 
Insert Table 2 about here 
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Associations between cannabis use and health issues are shown in Table 3 for all cannabis users 
and continuing cannabis users. Significant but low correlations (|r| < .30) are displayed for most 
outcomes. Both synchronous and longitudinal associations seemed higher for cannabis disorder 
symptoms rather than frequency of cannabis use. No clear longitudinal pathway between 
cannabis use and health issues appeared. 
 
Insert Table 3 about here 
 
The subsequent analyses focused on cannabis users only, and on the specific subgroup of 
continuing users who had values for both Time 1 and Time 2. Table 4 shows cannabis use among 
these subgroups of users. Both cannabis disorder symptoms and frequency of cannabis use 
exhibited similar levels at Times 1 and 2 for all cannabis users and continuing cannabis users. 
Thus, cannabis disorder symptoms and frequency of cannabis use did not differ across time 
among cannabis users. 
 
Insert Table 4 about here 
 
Longitudinal pathways between cannabis use and health issues 
Figure 2 presents the cross-lagged model examining the associations between cannabis disorder 
symptoms and health issues. Each variable at Time 1 significantly predicted the level of the same 
variable at Time 2. Moreover, number of cannabis disorder symptoms at Time 1 predicted 
depression, mental health, physical health and health consequences at Time 2. The reverse-causal 
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paths from health issues at Time 1 to cannabis disorder symptoms at Time 2 were non-
significant. 
 
Insert Figure 2 about here 
 
Figure 3 presents the cross-lagged model examining the association between frequency of 
cannabis use and health issues. Each variable at Time 1 also significantly predicted the level of 
the same variable at Time 2. Causal paths from frequency of cannabis use at Time 1 to health 
issues at Time 2 were all non-significant and reverse-causal paths from health issues at Time 1 to 
frequency of cannabis use at Time 2 were also non-significant. 
 
Insert Figure 3 about here 
 
Discussion 
We have described patterns of cannabis use among young Swiss males, and investigated 
prospective associations between cannabis use and health issues. Patterns of cannabis use 
showed that cannabis use was a stable phenomenon among young Swiss males in their early 
twenties. Indeed, 84.5% of participants remained in the same category (use/non-use) between 
Time 1 and Time 2, i.e. 15 months later in average. This result was consistent with previous 
studies which reported about 80% of continuity in cannabis use/non-use at young ages (24, 26-
28). Most of the participants who remained in the same category were non-users (61.9%). Only 
15.5% of participants changed category and showed transient patterns of cannabis use, with 8.3% 
being late onset users and 7.2% being matured out users. 
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The stability of patterns of cannabis use was investigated among all cannabis users and 
continuing cannabis users (i.e. participants who used cannabis 12 months prior to both Times 1 
and 2). The results showed that these users had stable patterns of cannabis use, as their number 
of cannabis disorder symptoms and frequency of cannabis use were similar across time. Previous 
studies showed that cannabis use was stable among young adults because initiation had occurred 
earlier (29, 30), and the present study highlighted that patterns of cannabis use were also stable 
across time in the studied sample. It seemed that patterns of cannabis use had already been 
established at this age in this population. This result may be useful for preventive purposes, as it 
reveals that interventions aimed against an initiation to cannabis and against cannabis use 
patterns should occur during teenage years, at least among young males in their early twenties.  
Longitudinal pathways between cannabis use and health issues were then tested. The results 
showed that cannabis disorder symptoms should be considered as a predictor of health issues, but 
that frequency of cannabis use should not, in line with the conclusions of studies reporting that 
frequency of cannabis use was not related to health issues (19, 22, 23). Indeed, cross-lagged 
panel models showed a causal path between cannabis disorder symptoms and health issues 
(depression, mental health, physical health, health consequences), but not reversed causal paths 
between health issues and cannabis disorder symptoms. It is interesting to see that the cannabis 
disorder symptoms lead to health issues despite its substantial continuity across time. Even a 
stable (i.e. not increasing) number of cannabis disorder symptoms may lead to poorer health 
outcomes. On the other hand, frequency of cannabis use did not predict health issues and so did 
not appear as a cause of deteriorated health. One can suspect that users reporting many cannabis 
disorder symptoms are also heavy cannabis users, but the frequency of cannabis use was 
controlled for in the cross-lagged model for cannabis disorder symptoms. Thereby, the number 
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of cannabis disorder symptoms seems not only to reflect the magnitude of use, but also 
something different in the style or type of use. 
 
This study had some limitations. The main one was that it did not include women. More studies 
are needed to see whether these patterns and causal pathways also fit women’s substance use 
behaviour. Another shortcoming was that the frequency of cannabis use was assessed using an 
ordinal scale. Further investigations with continuous scales are needed to more accurately 
capture the variability between cannabis users and patterns of use. A third limitation was the use 
of the number of cannabis disorder symptoms, which is not strictly speaking an assessment of 
cannabis dependence, even if it does give an overview of both cannabis abuse and dependence. 
Moreover, even if cross-lagged models allow the assessment of possible causal associations, they 
cannot prove causality (43). Evaluating causal relationships is especially hard when substance 
use is at focus, as individuals vulnerable to psychiatric disease may use more psychoactive 
substances than normal. Finally, data used in this study were self-reported. Although self-
reported data on risky behaviors and substance use are generally considered valid (44), it could 
introduce various  forms of bias including recall bias, pressure to give desirable answers and 
non-response bias. Self-rating for health issues, especially for depression and mental health 
assessment also did not allow knowing the factual clinical state of the participants. More 
investigations with external diagnosis are needed. However, SF12 and MDI are documented as 
reliable and validated measures of mental health status, with high responsiveness, sensitivity, 
empirical validity and associations with presence and seriousness of mental condition (33, 35). 
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For all these reasons, the results of this study should be interpreted cautiously and conclusions 
about causal pathways between health issues and cannabis use need more investigations, 
including external diagnosis for health-related outcomes and cannabis use. 
 
In conclusion, the substantive contributions of this study are twofold. First, cannabis use patterns 
(prevalence rates and changes in use, number of cannabis disorder symptoms and frequency of 
cannabis use) showed substantial continuity among young Swiss males in their early twenties. 
Although results for prevalence rates had been shown in previous studies, to our knowledge, 
none of them had underlined this phenomenon. This study also highlighted that not only were 
prevalence rates of cannabis use stable across time, but so were the ways in which continuing 
users used cannabis—at least for males at this young age of around 20 years old. Therefore, 
interventions dealing with cannabis use and heavy cannabis use should already target teenagers, 
as by their early twenties users have shown that they have settled patterns of use. Second, the 
clinically important measure of cannabis use was the number of symptoms of cannabis use 
disorder rather than the frequency of cannabis use, with cannabis disorder symptoms but not 
frequency of cannabis use predicting health issues. Prevention programmes should focus more 
on cannabis disorder symptoms than on the frequency of cannabis use, whilst not neglecting 
users who do not show higher number of cannabis disorder symptoms across time. 
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Table 1. Subgroups of cannabis users 
 
Cannabis use 
  Time 1 Time 2 
Non-users no no 
Continuing users yes yes 
Matured out users yes no 
Late onset users no yes 
  
24 
 
Table 2. Descriptive statistics for cannabis use and health issues 
    
Overall Non-users Continuing users Late onset users 
Matured 
out users 
N (%) 5,084 3,145 (61.9) 1,149 (22.6) 423 (8.3) 367 (7.2) 
Health issues (Time 1) 
     
 
Depression (0-50) 7.00 6.30 8.39 7.39 8.29 
 
Mental health (0-100) 47.35 48.30 45.47 46.53 46.04 
 
Physical health (0-100) 53.16 53.17 53.03 53.50 53.01 
 
Health consequences (0-7) 1.36 1.28 1.50 1.39 1.52 
Health issues (Time 2) 
     
 
Depression (0-50) 7.87 7.15 9.22 9.33 8.10 
 
Mental health (0-100) 45.32 46.16 43.59 43.94 45.15 
 
Physical health (0-100) 53.5 53.44 53.67 53.80 53.20 
  Health consequences (0-7) 1.49 1.42 1.64 1.59 1.51 
Non-users: no cannabis use 12 months prior to Times 1 and 2; continuing users, cannabis use 12 months prior to 
both Times 1 and 2; late onset users, cannabis use 12 months prior to Time 2, but not Time 1; matured out users, 
cannabis use 12 months prior to Time 1, but not Time 2. 
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Table 3. Associations between cannabis use and health-related issues 
   
Cannabis disorder symptoms   Frequency of cannabis use 
      Time 1 Time 2 
 
Time 1 Time 2 
All 
cannabis 
users 
(N=1,939) 
Time 1 
Depression .178*** .124*** 
 
.138*** .102*** 
Mental health -.142*** -.105*** 
 
-.105*** -.081*** 
Physical health -.042* -.021 
 
-.038 -.023 
Health consequences .067*** .037    .051* .057**  
Time 2 
Depression .137*** .154*** 
 
.098*** .130*** 
Mental health -.108*** -.128*** 
 
-.070** -.104*** 
Physical health -.025 -0.02 
 
-.030 -.022 
Health consequences .066*** .068***   0.45* .057** 
Continuing 
cannabis 
users 
(N=1,149) 
Time 1 
Depression  .238*** .201***    .102** .097**  
Mental health -.150*** -.148*** 
 
-.052 -.051 
Physical health -.131*** -.080** 
 
-.083** -.067* 
Health consequences .112*** .080**   .070* .069* 
Time 2 
Depression .198*** .202*** 
 
.061* .087** 
Mental health -.139*** -.162*** 
 
-.033 -.054 
Physical health -.121*** -.117*** 
 
-.097** -.123*** 
Health consequences .097*** .110***   .039 .084** 
* p < .05; ** < .01; *** p < .001. 
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 Table 4. Cannabis use among cannabis users 
      Time 1 Time 2 p-val. 
All cannabis users (N = 1,939) 
   
 
Age of first cannabis use 16.32 (2.44) - - 
 
Cannabis disorder symptoms1 4.89 (6.43) 4.70 (6.10) .114 
 
Frequency of cannabis use2 - - .755 
  
No cannabis use 21.8 18.9 - 
  
Monthly or less 44.0 46.0 - 
  
2-3 times a month 11.5 14.7 - 
  
2-3 times a week 7.8 7.4 - 
  
4-5 times a week 4.7 3.8 - 
  
Every day or almost every day 10.2 9.2 - 
Continuing cannabis users (N = 1,149) 
   
 
Age of first cannabis use 15.57 (1.96) - - 
 
Cannabis disorder symptoms1 7.09 (6.90) 6.81 (6.64) .066 
 
Frequency of cannabis use2 - - .203 
  
No cannabis use - - - 
  
Monthly or less 48.7 47.3 - 
  
2-3 times a month 16.5 20.8 - 
  
2-3 times a week 11.7 11.0 - 
  
4-5 times a week 7.3 5.8 - 
    Every day or almost every day 15.8 15.1 - 
1 Means and standard deviations are given, p-values refer to t-test for paired data. 
2 Percentages of use are given, p-values refer to related-samples Wilcoxon signed rank test. 
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Figure 1.  Illustration of cross-lagged longitudinal model 
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Figure 2. Cross-lagged model examining the associations between cannabis disorder symptoms 
and health issues 
For clarity, this figure only presents significant cross-lagged paths. However, all the cross-lagged paths depicted in 
Figure 1 were included in the final model, including within-time correlations between variables at both Time 1 and 
Time 2. Although not shown, the effect of age of onset of cannabis use disorder, language and frequency of cannabis 
use were controlled. 
* p < .05, *** p < .001. 
Standardized β are given. 
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Figure 3. Cross-lagged model examining the associations between frequency of cannabis use and 
health issues 
For clarity, this figure only presents significant cross-lagged paths. However, all the cross-lagged paths depicted in 
Figure 1 were included in the final model, including within-time correlations between variables at both Time 1 and 
Time 2. Although not shown, the effect of age of onset and language were controlled.  
Frequency of cannabis use equal zero was used as the reference category. 
*** p < .001.  
Standardized β are given. 
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